Molecular Therapy — Oncolytics · 2020 · 103 citations · 57 references
Life SciencesImmunologyOncologyCancer ImmunologyCell TherapyImmunotherapyCancer ImmunotherapyChimeric Antigen Receptor T-cell TherapyEffector T Cell FunctionHematologic Malignancy TherapyReceptor-mediated TargetingTumor-associated AntigensCar T Cell TrialsChimeric Antigen Receptor T-cell Therapy ToxicityCytokine Mediator ReleaseCytokine Release AssaysHematologic Malignancy Car T-cell TherapyTherapeutic Window DeterminationTherapeutic Window ManagementTumor Initiating Cells
. We further demonstrated a pre-clinical proof of concept for the safety-switch mechanism using a hematotoxicity mouse model wherein TM123-redirected UniCAR-T showed reversible toxicity toward hematopoietic cells compared to CD123 CAR-T. In conclusion, UniCAR-T maintain full anti-leukemic efficacy, while ensuring rapid controllability to improve safety and versatility of CD123-directed immunotherapy. The safety and efficacy of UniCAR-T in combination with TM123 will now be assessed in a phase I clinical trial (ClinicalTrials.gov: NCT04230265).
57
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett et al. · New England Journal of Medicine · 2017 · 5.9K citations · Full text
Medicine, Hematology, Oncology +16
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude, Noelle V. Frey, Pamela A. Shaw et al. · New England Journal of Medicine · 2014 · 5.4K citations · Full text
A cell initiating human acute myeloid leukaemia after transplantation into SCID mice
Tsvee Lapidot, Christian Sirard, Josef Vormoor et al. · Nature · 1994 · 4.7K citations
Medicine, Cell Biology, Hematology +14